NO164418B - Analogifremgangsmaate for fremstilling av terapeutisk aktive naftyridin- og kinolin-karboksylsyre-forbindelser. - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive naftyridin- og kinolin-karboksylsyre-forbindelser. Download PDFInfo
- Publication number
- NO164418B NO164418B NO833206A NO833206A NO164418B NO 164418 B NO164418 B NO 164418B NO 833206 A NO833206 A NO 833206A NO 833206 A NO833206 A NO 833206A NO 164418 B NO164418 B NO 164418B
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- formula
- compound
- oxo
- dihydro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 9
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical class C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- -1 2-thiazolyl ring Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 229910001868 water Inorganic materials 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- OQCUGPQOZNYIMV-UHFFFAOYSA-N pyrrolidin-3-ylmethanamine Chemical class NCC1CCNC1 OQCUGPQOZNYIMV-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FKKUVCHFRDLBHN-UHFFFAOYSA-N 1-ethyl-6,7,8-trifluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C(F)=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 FKKUVCHFRDLBHN-UHFFFAOYSA-N 0.000 description 4
- LJYJAEQCLXAHFQ-UHFFFAOYSA-N 7-chloro-1-ethyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound FC1=C(Cl)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 LJYJAEQCLXAHFQ-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- QIBBUPLIXPNTCV-UHFFFAOYSA-N ethyl 7-[4-(chloromethyl)-1,3-thiazol-2-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylate Chemical compound FC=1C=C2C(=O)C(C(=O)OCC)=CN(CC)C2=CC=1C1=NC(CCl)=CS1 QIBBUPLIXPNTCV-UHFFFAOYSA-N 0.000 description 3
- BUQMHUKZYMREQT-UHFFFAOYSA-N n-(pyrrolidin-3-ylmethyl)ethanamine Chemical compound CCNCC1CCNC1 BUQMHUKZYMREQT-UHFFFAOYSA-N 0.000 description 3
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 2
- KADAPIRHXVRMJV-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-[3-(methylaminomethyl)pyrrolidin-1-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(CNC)C1 KADAPIRHXVRMJV-UHFFFAOYSA-N 0.000 description 2
- VDLUURWHKGLOHH-UHFFFAOYSA-N 1-ethyl-7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CNCC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2CC VDLUURWHKGLOHH-UHFFFAOYSA-N 0.000 description 2
- BQDVLIDLHOSQHC-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical class N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(N)C1 BQDVLIDLHOSQHC-UHFFFAOYSA-N 0.000 description 2
- KFBDAMQESLTGCT-UHFFFAOYSA-N 7-[3-(aminomethyl)pyrrolidin-1-yl]-1-ethyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(CN)C1 KFBDAMQESLTGCT-UHFFFAOYSA-N 0.000 description 2
- BAWJTQWTEJOBTP-UHFFFAOYSA-N 7-[3-(aminomethyl)pyrrolidin-1-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(CN)C1 BAWJTQWTEJOBTP-UHFFFAOYSA-N 0.000 description 2
- LWJQCGJFFGOFHD-UHFFFAOYSA-N 7-[4-(chloromethyl)-1,3-thiazol-2-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1C1=NC(CCl)=CS1 LWJQCGJFFGOFHD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- MXEUIOKSQAFQHK-UHFFFAOYSA-N ethyl 7-[4-(aminomethyl)-1,3-thiazol-2-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylate Chemical compound FC=1C=C2C(=O)C(C(=O)OCC)=CN(CC)C2=CC=1C1=NC(CN)=CS1 MXEUIOKSQAFQHK-UHFFFAOYSA-N 0.000 description 2
- NBKXDFNBDPCUBK-UHFFFAOYSA-N ethyl 7-[4-(azidomethyl)-1,3-thiazol-2-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylate Chemical compound FC=1C=C2C(=O)C(C(=O)OCC)=CN(CC)C2=CC=1C1=NC(CN=[N+]=[N-])=CS1 NBKXDFNBDPCUBK-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- JVODWNWKCOVKTO-UHFFFAOYSA-N n-methyl-1-pyrrolidin-3-ylmethanamine Chemical compound CNCC1CCNC1 JVODWNWKCOVKTO-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 150000005058 1,8-naphthyridines Chemical class 0.000 description 1
- MHFJYVWFBPABTI-UHFFFAOYSA-N 1-ethyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHFJYVWFBPABTI-UHFFFAOYSA-N 0.000 description 1
- OZVAPLKMUZWYCP-UHFFFAOYSA-N 1-ethyl-6,8-difluoro-4-oxo-7-[3-[(propan-2-ylamino)methyl]pyrrolidin-1-yl]quinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(CNC(C)C)C1 OZVAPLKMUZWYCP-UHFFFAOYSA-N 0.000 description 1
- XGJFDWRVYBIBHL-UHFFFAOYSA-N 1-ethyl-6,8-difluoro-7-[3-[(2-hydroxyethylamino)methyl]pyrrolidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(CNCCO)C1 XGJFDWRVYBIBHL-UHFFFAOYSA-N 0.000 description 1
- XCNQAVKDYDUMRV-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-[3-(methylaminomethyl)pyrrolidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(CNC)C1 XCNQAVKDYDUMRV-UHFFFAOYSA-N 0.000 description 1
- BAYYCLWCHFVRLV-UHFFFAOYSA-N 1-ethyl-7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CNCC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CC)C2=C1F BAYYCLWCHFVRLV-UHFFFAOYSA-N 0.000 description 1
- FLUKWNOQCRPLGK-UHFFFAOYSA-N 1-ethyl-7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(CNCC)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2CC FLUKWNOQCRPLGK-UHFFFAOYSA-N 0.000 description 1
- DDVRNOMZDQTUNS-UHFFFAOYSA-N 2,7-diazaspiro[4.4]nonane Chemical compound C1NCCC11CNCC1 DDVRNOMZDQTUNS-UHFFFAOYSA-N 0.000 description 1
- NSCCOUBDHCHVHL-UHFFFAOYSA-N 2-(pyrrolidin-3-ylmethylamino)ethanol Chemical compound OCCNCC1CCNC1 NSCCOUBDHCHVHL-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 1
- NVVIXKGACSGLKH-UHFFFAOYSA-N 7-(2,7-diazaspiro[4.4]nonan-2-yl)-1-ethyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N(C1)CCC21CCNC2 NVVIXKGACSGLKH-UHFFFAOYSA-N 0.000 description 1
- UDRVIUPLBFPNPO-UHFFFAOYSA-N 7-[3-(aminomethyl)pyrrolidin-1-yl]-6,8-difluoro-1-(2-fluoroethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CN)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F UDRVIUPLBFPNPO-UHFFFAOYSA-N 0.000 description 1
- DYJAOVPMMTZXCS-UHFFFAOYSA-N 7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6,8-difluoro-1-(2-fluoroethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(CNCC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F DYJAOVPMMTZXCS-UHFFFAOYSA-N 0.000 description 1
- WNNSMMJBBOPPOT-UHFFFAOYSA-N 7-chloro-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(Cl)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 WNNSMMJBBOPPOT-UHFFFAOYSA-N 0.000 description 1
- VTTPHBIBXCPVID-UHFFFAOYSA-N 7-pyridin-2-ylquinoline Chemical class N1=CC=CC=C1C1=CC=C(C=CC=N2)C2=C1 VTTPHBIBXCPVID-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- SQZFPSKCCXTATL-UHFFFAOYSA-N CCCN1CC=CC2=C1N=CC(=C2)C(=O)O Chemical compound CCCN1CC=CC2=C1N=CC(=C2)C(=O)O SQZFPSKCCXTATL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 150000005130 benzoxazines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- GKONDLRZGSAWIZ-UHFFFAOYSA-N ethyl 3-(2-ethoxy-2-oxoethyl)-5-oxopyrrolidine-3-carboxylate Chemical compound CCOC(=O)CC1(C(=O)OCC)CNC(=O)C1 GKONDLRZGSAWIZ-UHFFFAOYSA-N 0.000 description 1
- JQWHWPOPTBYMDT-UHFFFAOYSA-N ethyl 7-carbamothioyl-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylate Chemical compound NC(=S)C1=C(F)C=C2C(=O)C(C(=O)OCC)=CN(CC)C2=C1 JQWHWPOPTBYMDT-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WTRWSSDZHQOPJI-UHFFFAOYSA-N methyl 1-benzyl-5-oxopyrrolidine-3-carboxylate Chemical compound O=C1CC(C(=O)OC)CN1CC1=CC=CC=C1 WTRWSSDZHQOPJI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KYOLWTXOYMKDRP-UHFFFAOYSA-N n-(pyrrolidin-3-ylmethyl)propan-1-amine Chemical compound CCCNCC1CCNC1 KYOLWTXOYMKDRP-UHFFFAOYSA-N 0.000 description 1
- VJPYEYRKXXVWNA-UHFFFAOYSA-N n-(pyrrolidin-3-ylmethyl)propan-2-amine Chemical compound CC(C)NCC1CCNC1 VJPYEYRKXXVWNA-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical class C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Quinoline Compounds (AREA)
Description
US-patent 4.341.784 beskriver visse substituerte 7-(3-amino-l-pyrrolidinyl)-l-etyl-6-fluor-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyrer med den generelle formel:
Forbindelsene er angitt å ha antibakteriell aktivitet.
The Journal of Medicinal Chemistry, 23, 1358 (1980) beskriver visse substituerte kinolin-3-karboksylsyrer med formelen
hvor
kan være pyrrolidinyl. Se også US-patent 4.146.719. Forbindelsene er angitt å ha antibakteriell aktivitet.
Europeisk patentansøkning 8}. 10 6747, publikasjonsnummer 047,005, publisert 10. mars 1982, beskriver visse benzoksazin-derivater med formelen
hvor A er halogen og B kan være en cyklisk amin-substituent så som pyrrolidin eller piperidin.
Visse 7-heterocyklisk-substituerte 1,8-naftyridiner er beskrevet i Eur. J. Med., Chem. - Chimica Therapeutica, 29, 27
(1977).. US-patenter 3,753,993 og 3,907,808 beskriver visse 7-pyridyl-kinoliner.
Publikasjonene angir at disse forbindelser har antibakteriell aktivitet.
Foreliggende oppfinnelse angår fremstilling av en forbindelse med formel i
hvor X er CH, CF eller N; når X er CH, er Z en l-pyrrolidinyl-ring eller en 2-tiazolyl-ring som er substituert med en gruppe -CH2-NHR4, R4 er valgt blant hydrogen eller C1-C4 alkyl, og R2 er etyl, når X er CF, er Z en usubstituert 2,7-diazaspiro[4,4]non-2-yl-ring eller en l-pyrrolidinyl-ring som er substituert med en gruppe -CH2-NHR5, R5 er valgt blant hydrogen, C1-C4 alkyl eller hydroksy(C2-C4)alkyl, og R2 er etyl eller 2-fluoretyl, når X er N, er Z en l-pyrrolidinyl-ring som er substituert med en gruppe -CH2-NHR4, R4 er som definert ovenfor, og R2 er etyl; og de farmasøytisk godtagbare syreaddisjonssalter eller basesalter derav, Ifølge oppfinnelsen tilveiebringes en fremgangsmåte for fremstilling av forbindelser med formelen I, og den karak-teriseres ved at a) for fremstilling av en forbindelse med formel I hvor Z er substituert 1-pyrrolidinyl eller usubstituert 2,7-diazaspiro-[4,4]non-2-yl, omsettes en forbindelse med formelen
hvor L er et halogenatom, og X og R2 er som angitt ovenfor, med et amin svarende til gruppen Z angitt ovenfor, eller
b) for fremstilling av en forbindelse med formelen
hvor X, R2 og R4 er som angitt ovenfor, 1) omsettes en forbindelse med formelen
hvor R^ er C1- C4 alkyl,
med en forbindelse med formelen
hvor Hal er halogen; 2) halogenatomet i den resulterende forbindelse med formelen utskiftes med en aminogruppe med formelen HR4N- eller med et azid-ion; 3) den resulterende azidgruppe reduseres for å gi en forbindelse hvor R4 er hydrogen, og 4) eventuelt alkyleres aminogruppen med et alkylnalogenid hvor alkylgruppen har 1 til 3 karbonatomer, og 5) forbindelsen med formel I oppnås ved sur hydrolyse,
og eventuelt omdannes det resulterende produkt til et farma-søytisk godtagbart syreaddisjonssalt eller basesalt derav ved kjente metoder.
De nye forbindelser fremstilt ifølge oppfinnelsen kan til-beredes til et farmasøytisk preparat ved at en antibakterielt effektiv mengde av en forbindelse med formel I og farmasøytisk godtagbare salter derav blandes med et farmasøytisk godtagbart bæremiddel.
For behandling av bakterieinfeksjoner hos pattedyr admini-streres en antibakterielt effektiv mengde av et slikt preparat til et pattedyr med behov for behandling.
Utgangsforbindelsene med formel Ia er kjente. Således
er de følgende forbindelser beskrevet i de angitte publikasjoner:
Europeisk patentansøkning 80 40 1369
J. Med. Chem., 23, 1358 (1980) Europeisk patent O OOO 203 (1979)
Britisk patent 2,057,440
Aminene svarende til gruppen Z er enten kjente forbindelser eller de kan fremstilles av kjente utgangsmaterialer ved standardmetoder eller ved variasjoner derav. F.eks. kan 3-pyrrolidinmetanaminer med formel D hvor bl.a. er hydrogen, lett fremstilles fra det kjente utgangsmateriale metyl-5-okso-l-(fenylmetyl)-3-pyrrolddin-karboksylat, A, (J. Org. Chem. , 2_6, 1519 (1961)) ifølge det følgende reaksjonsforløp:
Forbindelsen hvor R, er hydrogen, nemlig 3-pyrrolidinmetanamin, er beskrevet i J. Org. Chem., 2j5, 4955 (1961).
Når R^ = H i C, kan den primære aminfunksjon beskyttes med en gruppe R4 som definert ovenfor.
Spiroaminforbindelsen svarende til Z kan lett fremstilles fra det kjente utgangsmateriale 3-etoksykarbonyl-5-okso-3-pyrrolidin-eddiksyre-etylester (J. Org. Chem., 46, 2757
(1981)) ved hjelp av det følgende reaksjonsforløp:
Forbindelsene fremstilt ifølge oppfinnelsen har antibakteriell aktivitet når de undersøkes ved mikrotitreringsfortynningsmetoden beskrevet av Heifetz et al, Antimicr. Agents & Chemoth., 6, 124
(1974).
Ved anvendelse av ovennevnte metode ble de følgende minimum hemmende konsentrasjonsyerdier (MIC i pg/ml) oppnådd for representative forbindelser fremstilt ifølge oppfinnelsen og den tidligere kjente forbindelse 7-(3-amino-l-pyrrolidinyl)-l-etyl-6-fluor-l,4-dihydro-4-okso-l,8-naftyridin-3-karboksylsyre betegnet som <**>
i tabellen.
Tilsvarende sammenligningsforsøk ble foretatt med forbindelsen i eksempel 56 i Kogas artikkel i J. Med. Chem., 23 (1980), s. 1358, og forbindelsen ifølge eksempel 7 i henhol til oppfinnelsen, med følgende resultat:
Forbindelsene fremstilt ifølge oppfinnelsen kan danne både farmasøytisk godtagbare syreaddisjonssalter og/eller base-
salter. Basesalter dannes med metaller eller aminer, så som alkali- og jordalkalimetaller eller organiske aminer. Eksempler på metaller som anvendes som kationer, er natrium, kalium, magnesium, kalsium og lignende. Eksempler på egnede aminer er N,N'-dibenzyletylendiamin, klorprokain, cholin, dietanolamin, etylendiamin, N-metylglukamin og prokain.
Farmasøytisk godtagbare syreaddisjonssalter dannes med organiske og uorganiske syrer.
Eksempler på egnede syrer for saltdannelse er saltsyre, svovelsyre, fosforsyre, eddiksyre, sitronsyre, oksalsyre, malon-syre, salicylsyre, eplesyre, glukonsyre, fumarsyre, ravsyre, askorbinsyre, maleinsyre, metansulfonsyre, o.l. Saltene fremstilles ved at den frie baseform bringes i kontakt med en til-strekkelig mengde av den ønskede syre for å danne f.eks. et mono- eller di-sålt på vanlig måte. De frie baseformer kan regenereres ved å behandle saltformen med en base. F.eks. kan man benytte fortynnede oppløsninger av vandig base. Fortynnede vandige oppløsninger av natriumhydroksyd, kaliumkarbonat, ammoniakk og natriumbikarbonat er egnet for dette formål. Den frie baseform adskiller seg fra sine respektive saltformer noe med hensyn til fysikalske egenskaper så som oppløselighet i polare oppløsningsmidler, men saltene er ellers likeverdige med sine respektive frie baseformer for denne oppfinnelses formål. Anvendelse av overskudd base hvor R' er hydrogen fører til det tilsvarende basiske salt.
Forbindelsene fremstilt ifølge oppfinnelsen kan eksistere i usolvatiserte så vel som solvatiserte former, innbefattet hydratiserte former. Generelt er de solvatiserte former, innbefattet hydratiserte former og lignende, likeverdige med de usolvatiserte former for denne oppfinnelses formål.
De alkylgrupper det her er tale om omfatter både lineære og forgrenede karbonkjeder med fra 1 til ca. 3 karbonatomer, bortsett fra når det er direkte angitt at de kan inneholde mer enn 3 karbonatomer. Representative slike grupper er metyl, etyl, propyl, isopropyl og lignende.
Eksempel 1
7-[ 3-( aminometyl)- 1- pyrrolldinyl]- l- etyl- 6- fluor- 1, 4- dihydro-4- okso- l, 8- naftyrldln- 3- karboksylsyre
En blanding av 2,00 g (7,39 mmol) 7-klor-l-etyl-6-fluor-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyre, 250 ml acetonitril og 2,22 g (22,17 mmol) 3-pyrrolidinmetanamin [J. Org.
Chem., 26, 4955 (1961)] ble omrørt ved romtemperatur i 4 dager. Reaksjonsblandingen ble filtrert, og bunnfallet ble oppløst i
500 ml ammoniumhydroksyd ved pH 10,5. Denne oppløsning ble filtrert, og oppløsningsmidlet ble fjernet under redusert trykk. Produktet ble vasket med 2 x 10 ml vann, og derefter med etanol/ eter (1:1) inntil det var tørt, for å gi 1,65 g 7-[3-(aminometyl)-1-pyrrolidinyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-l,6-naftyridin-3- karboksylsyre, sm.p. 217-218,5°C.
Analyse:
Beregnet for C16<H>19<FN>4<0>3-1/2 H20: C 55,97, H 5,87, N 16,32 Funnet:r C 55,89, H 5,66, N 16,33
Eksempel 2 l- etyl- 6- fluor- 1, 4- dihydro- 7-[ 3-[( metylamino) metyl]- 1- pyrrolidinyl]-4- okso- l, 8- naftyridin- 3- karboksylsyre
1,00 g (3,69 mmol) 7-klor-l-etyl-6-fluor-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyre, 40 ml acetonitril og 1,27 g (11,08 mmol) N-metyl-3-pyrrolidinmetanamin ble omrørt ved romtemperatur i 3 dager. Reaksjonsblandingen ble filtrert, og bunnfallet ble oppløst i vandig ammoniumhydroksyd ved pH 11. Oppløsningen ble filtrert, og oppløsningsmidlet ble fjernet under redusert trykk. Produktet ble vasket med 5 ml vann, 10 ml etanol/eter (1:1) og til slutt med eter inntil det var tørt for å gi 0,571 g l-etyl-6-fluor-1,4-dihydro-7-[3-[(metylamino)-metyl]-1-pyrrolidinyl]-4-okso-l,8-naftyridin-3-karboksylsyre,
sm.p. 251-253°C.
Analyse:
Beregnet for c17<H>2iFN4°3*1/2 H20: c 57»13' H 6,20, N 15,68 Funnet: C 57,19, H 6,03, N 15,85.
Eksempel 3
l-etyl-7-[3-[( etylamino) metyl]- 1- pyrrolidinyl]- 6- fluor- 1, 4- dihydro-4- okso- l, 8- naftyridin- 3- karboksylsyre
1,00 g (3,69 mmol) 7-klor-l-etyl-6-fluor-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyre, 100 ml acetonitril og 1,42 g (11,08 mmol) N-etyl-3-pyrrolidinmetanamin ble omrørt i 3 dager ved romtemperatur. Reaksjonsblandingen ble derefter filtrert,
og bunnfallet ble vasket med vann, etanol/eter (1:3) og til slutt med eter til det var tørt, for å gi 0,715 g l-etyl-7-[3-[(etylamino)metyl]-1-pyrrolidinyl]-6-fluor-1,4-dihydro-4-okso-1,8-naftyridin-3-karboksylsyre, sm.p.: 229,5-231,5°C.
Analyse:
Beregnet for C18H23FN403^0,24 H20: C 58,94, H 6,45, N 15,27, H20 1,20 Funnet: C 58,28, H 6,85, N 14,90, H20 0,80.
Eksempel 4
l- etyl- 6- fluor- 1, 4- dihydro- 4- okso- 7-[ 3-[( propylamino) metyl]- 1-pyrrolidinyl]- 1, 8- propyl- naftyridin- 3- karboksylsyre
En tilnærmet oppløsning av 0,82 g (3,0 mmol) 7-klor-l-etyl-6-fluor-1,4-dihydro-4-okso-l,8-naftyridin-3-karboksylsyre og 1,4 g (10 mmol) N-propyl-3-pyrrolidinmetanamin i 50 ml acetonitril ble oppvarmet under tilbakeløpskjøling i 4 timer. Oppløsnings-midlet ble fjernet i vakuum, residuet ble oppløst i vann og filtrert gjennom en fiberglasspute for klaring, og filtratet ble regulert til pH 1,8 med 6M saltsyre. Den resulterende klare oppløsning ble lyofilisert, og residuet ble omkrystallisert fra etanol for å gi 400 mg l-etyl-6-fluor-1,4-dihydro-4-okso-7-[3-[(propylamino)metyl]-1-pyrrolidinyl]-1,8-propyl-naftyridin-3-karboksylsyre, sm.p. 281-283°C som hydrokloridet.
Eksempel 5
7-[ 3-( aminometyl)- 1- pyrrolidinyl]- l- etyl- 6- fluor- 1, 4- dihydro-4- okso- 3- kinolinkarboksylsyre
En blanding av 1,00 g (3,95 mmol) 6,7-difluor-l-etyl-:l,4-dihydro-4-okso-3-kinolinkarboksylsyre, 40 ml acetonitril og 1,28 g (12,75 mmol) 3-pyrrolidinmetanamin ble omrørt natten over ved romtemperatur. Reaksjonsblandingen ble filtrert, bunnfallet vasket med 10 ml vann, etanol/eter (1:1) og til slutt med eter til tørrhet for å gi 1,13 g 7-[3-(aminometyl)-1-pyrrolidinyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre,
sm.p. 234-236°C.
Analyse:
Beregnet for c17<H>2oFN3°3"3H20: C 60,27, H 6,13, N 12,40
Funnet: C 60,63, H 5,85, N 12,01.
Eksempel 6
l- etyl- 6- fluor- 1, 4- dihydro- 7-[ 3-[( metylamino) metyl]- 1- pyrrolidinyl]-4- okso- 3- kinolinkarboksylsyre
En blanding av 1,00 g (3,95 mmol) 1-ety1-6,7-difluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre, 10 ml N,N-dimetylformamid, 75 ml acetonitril og 1,35 g (11,85 mmol) N-metyl-3-pyrrolidinmetanamin ble tilbakeløpsbehandlet natten over. Reaksjonsblandingen ble avkjølt til romtemperatur og filtrert. Bunnfallet ble vasket med vann, étanol/eter (1:3) og til slutt med eter til tørrhet for å gi 1,17 g l-etyl-6-fluor-1,4-dihydro-7-[3-[(metylamino)-metyl]-1-pyrrolidinyl]-4-okso-3-kinolinkarboksylsyre,
sm.p. 247-250°C.
Analyse:
Beregnet for ClgH22FN303'1/2H20: C 60,66, H 6,50, N 11,79 Funnet: C 60,69, H 6,30, N 11,82
Eksempel 7 l- etyl- 7-[ 3- [ ( etylamino) metyl]- 1- pyrrolidinyl]- 6- fluor- 1, 4-dihydro- 4- okso- 3- k inolinkarboksy1syre
En blanding av 2,70 g (10,0 mmol) 7-klor-l-etyl-6-fluor-l,4-dihydro-4-okso-3-kinolinkarboksylsyre, 60 ml B-pikolin og 3,85 g (30,0 mmol) N-etyl-3-pyrrolidinmetanamin ble tilbakeløps-behandlet natten over. Reaksjonsblandingen ble avkjølt til romtemperatur, 100 ml konsentrert ammoniumhydroksyd ble tilsatt,
og oppløsningsmidlene ble fjernet under redusert trykk. En opp-løsning av 200 ml diklormetan/eter (1:3) ble tilsatt. Det resulterende bunnfall ble frafiltrert, vasket med etanol/eter (1:3) og til slutt med eter til det var tørt, for å gi 1,87 g l-etyl-7-[3-[(etylamino)metyl]-1-pyrrolidinyl]-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre, sm.p. 248-252°C. Analyse: Beregnet for C19H24FN303-1,48H20: C 58,81, H 7,00, N 10,83 Funnet: C 58,70, H 6,53, N 10,85. Eksempel 8 7-[ 3-( aminometyl)- 1- pyrrolidinyl]- l- etyl- 6, 8- difluor- 1, 4- dihydro-4- okso- 3- klnolinkarboksylsyre En blanding av 0,50 g (1,84 mmol) l-etyl-6,7,8-trifluor-l,4-dihydro-4-okso-3-kinolinkarboksylsyre, 5 ml acetonitril, • 0,28 g (1,84 mmol) 1,8-diazabicyklo[5.4.0]undec-7-en og 0,19 g (1,94 mmol) 3-pyrrolidinmetanamin ble tilbakeløpsbehandlet i 1 time og derefter omrørt ved romtemperatur natten over. Reaksjonsblandingen ble filtrert, og bunnfallet ble vasket med etyleter for å gi 0,56 g 7-[3-(aminometyl)-1-pyrrolidinyl]-1-ety1-6,8-difluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre, sm.p. 219-221°C.
Følgende forbindelse ble også fremstilt ved fremgangsmåten ovenfor: 7-[3-(aminometyl)-1-pyrrolidinyl]-6,8-difluor-1-(2-fluoretyl)-I, 4-dihydro-4-okso-3-kinolinkarboksylsyre, sm.p. 224-226°C ( 8a).
Eksempel 9
l- etyl- 7-[ 3-[( etylamincjmetyl]- 1- pyrrolidinyl]- 6, 8- difluor- 1, 4-dihydro- 4- okso- 3- kinolinkarboksylsyre
En blanding av 22,50 g (83,03 mmol) l-etyl-l,4-dihydro-4-okso-6,7,8-trifluor-3-kinolinkarboksylsyre, 225 ml acetonitril, II, 25 g (87,08 mmol) N-etyl-3-pyrrolidinmetanamin og 12,6 g (83,03 mmol) l,8-diazabicyklo[5.4.0]undec-7-en ble tilbakeløps-behandlet i 1 time bg ble derefter omrørt ved romtemperatur natten over. Det faste stoff ble frafiltrert og vasket med eter for å gi 26,33 g l-etyl-7-[3-[(etylamino)metyl]-1-pyrrolidinyl]-6,8-difluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre, sm.p. 208-210°C.
Analyse:
Beregnet for <C>19H23<F>2<N>3°3<:> C 6o'15' H 6,11, N 11,08
Funnet: C 59,85, H 6,17, N 11,08.
Følgende forbindelse ble også fremstilt ved fremgangsmåten ovenfor: 7-[3-[(etylamino)metyl]-1-pyrrolidinyl]-6,8-difluor-1-(2-fluoretyl)-l,4-dihydro-4-okso-3-kinolinkarboksylsyre, sm.p. 221-223°C (lia).
Eksempel lo 1- etyl- 6, 8- difluor- 1,4-dihydro-7-[ 3-[[( 2- hydroksyetyl) amlno]-metyl]- 1- pyrrolidlnyl]- 4- okso- 3- kinolin- karboksylsyre
En blanding av 0,50 g (1,84 mmol) l-etyl,6,7,8-trifluor-4-okso-kinolin-3-karboksylsyre, 5 ml acetonitril, 0,28 g (1,84 itonol) 1,8-diazabicyklo[5.4.0]undec-7-en og 0,28 g (1,94 mmol) 2- [(3-pyrrolidinylmetyl)amino]etanol ble tilbakeløpsbehandlet i 1 time og derefter omrørt ved romtemperatur natten over. Reaksjonsblandingen ble filtrert, og bunnfallet ble vasket med
eter til tørrhet for å gi 0,58 g l-etyl-6,8-difluor-1,4-dihydro-7-[3-[[(2-hydroksyetyl)amino]metyl]-1-pyrrolidinyl]-4-okso-3-kinolin-karboksylsyre, sm.p. 215-216°C.
Anvendelse av tre ekvivalenter N-(2-propyl)-3-pyrrolidinmetanamin og intet 1,8-diazabicyklo[5.4.0)undec-7-en ved fremgangsmåten ovenfor, ga l-etyl-7-[3-[[(l-metyletyl)amino]metyl]-1-pyrrolidinyl]-6,8-difluor-1,4-dihvdro-4-okso-3-kinolin-karboksylsyre, sm.p. 198-200°C (10*).
Eksempel 11
1- etyl- 6, 8- difluor- 1, 4- dihydro- 7-( 2, 7- diazaspiro[ 4, 4] non- 2- yl)-4- okso- 3- kinolin- karboksylsyre
En suspensjon av 0,81 g (3,0 mmol) l-etyl-6,7,8-trifluor-4-okso-1,4-dihydrokinolin-3-karboksylsyre i 40 ml acetonitril ble behandlet med 0,80 g (6,3 mmol) 2,7-diazaspiro[4,4]nonan [J. Org. Chem. 4_6, 2757 (1981)], og blandingen ble omrørt i 2 dager ved romtemperatur, tilbakeløpsbehandlet i 1,5 timer, avkjølt og filtrert for å gi 1,17 g av tittelforbindelsen, sm.p. 234-240°C (dek.).
Analyse:
Beregnet for <c>i9<H>2iN3F2°3: C 60,47, H 5,61, N 11,13
Funnet: C 60,17, H 5,46, N 11,11.
Eksempel 12 7- [ 4- ( aminometyl) - 2- tlaz. olyl] - l- etyl- 6- f luor- 1, 4- dihydro- 4- okso-3- kinolin- karboksylsyré
En oppløsning av 0,16 g (0,5 mmol) etyl-l-etyl-6-fluor-7-tiokarbamoyl-l,4-dihydro-4-okso-3-kinolin-karboksylat og 0,32 g (2,5 mmol) 1,3-dikloraceton i 3 ml N,N-dimetylformamid ble opp-varmet 3,5 timer på et dampbad. Fortynning av den avkjølte reaksjonsblanding med etylacetat ga 0,12 g produkt som ble omkrystallisert fra kloroform:etylacetat for å gi 0,08 g etyl-7-[4-(klormetyl)-2-tiazolyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylat, sm.p. 214-215°C (dek.).
En blanding av 1,10 g (2,78 mmol) etyl-7-f4-(klormetyl)-2-tiazolyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylat og 0,50 g (7,6 mmol) natriumazid i 50 ml N,N-dimetylformamid ble oppvarmet på dampbad i 4 timer. Efter inndampning til nær tørrhet ble 50 ml tilsatt for å gi 1,01 g produkt som ble krystallisert fra etanol for å gi 0,91 g etyl-7-[4-(azidometyl)-2- tiazolyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylat, sm.p. 192-194° (dek.).
En oppløsning av 0,87 g (2,17 mmol) etyl-7-[4-(azidometyl)-2-tiazolyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylat i 125 ml eddiksyre ble omrørt med 0,10 g 10% palladium-på-kull-katalysator, og hydrogengass ble boblet gjennom i 1,5 timer. Efter filtrering, avdampning av oppløsningsmiddel og utgnidning med eter fikk man 0,77 g etyl-7-[4-(aminometyl)-2-tiazolyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylat.
En oppløsning av 0,70 g (1,87 mmol) etyl-7-[4-(aminometyl)-2-tiazolyl]-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylat i 15 ml 6N saltsyre ble oppvarmet på dampbad i 2,25 timer. Efter tilsetning av 15 ml vann ble blandingen avkjølt til 0° og filtrert. Det oppsamlede faste stoff ble suspendert i 8 ml vann, oppløst ved pH 11 med 2N natriumhydroksyd, og utfelt påny ved tilsetning av 2N saltsyre til pH 6. Produktet (0,37 g) ble krystallisert to ganger fra N,N-dimetylformamid for å gi 0,19 g 7-[4-(aminometyl)-2-tiazolyl]-l-etyl-6-fluor-1,4-diklor-4-okso-3-kinolin-karboksylsyre, sm.p. 224-226°C (dek.).
Eksempel 13
l- etyl- 6- fluor- 1, 4- dlhydro- 7-[ 4-[( metylamino) metyl]- 2- tiazolyl]-4- okso- 3- klnolin- karboksylsyre
En oppløsning av 0,61 g (1,54 mmol) 7-(4-klormetyl-2-tiazolyl)-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylsyre-etyl-ester i 20 ml 6N saltsyre ble tilbakeløpsbehandlet i 2 timer og inndampet til tørrhet. Det resulterende faste stoff ble suspendert i varmt vann, filtrert og.tørket for å gi 0,48 g rått produkt, 7-(4-klor-metyl-2-tiazolyl)-l-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylsyre.
En oppløsning av 0,40 g 7-(4-klormetyl-2-tiazolyl)-1-etyl-6-fluor-1,4-dihydro-4-okso-3-kinolin-karboksylsyre i 100 ml 40% vandig metylamin ble omrørt ved romtemperatur natten over og inndampet til tørrhet. Det resulterende faste stoff ble krystallisert fra vann for å gi 0,33 g av tittelforbindelsen, sm.p. 216-218°C (dek.).
Analyse:
Beregnet for Cl7<H>1<6>N3F03S-0,2H20: C 55,94, H 4,53, N 11,51 Funnet: C 55,92, H 4,41, N 11,18.
Claims (1)
- Analogifremgangsmåte for fremstilling av en terapeutisk aktiv forbindelse med formelen:hvor X er CH, CF eller N;når X er CH, er Z en l-pyrrolidinyl-ring eller en 2-tiazolyl-ring som er substituert med en gruppe -CH2-NHR4, R4 er valgt blant hydrogen eller C^-C^j alkyl, og R2 er etyl,når X er CF, er Z en usubstituert 2,7-diazaspiro[4,4]non-2-yl-ring eller en l-pyrrolidinyl-ring som er substituert med engruppe -CH2-NHR5, R5 er valgt blant hydrogen, C;l-C4 alkyl eller hydroksy(C2-C4)alkyl, og R2 er etyl eller 2-fluoretyl,når X er N, er Z en l-pyrrolidinyl-ring som er substituert med en gruppe -CH2-NHR4, R4 er som definert ovenfor, og R2 er etyl;og de farmasøytisk godtagbare syreaddisjonssalter eller basesalter derav, karakterisert ved at a) for fremstilling av en forbindelse med formel I hvor Z er substituert 1-pyrrolidinyl eller usubstituert 2,7-diazaspiro-[4,4]non-2-yl, omsettes en forbindelse med formelenhvor L er et halogenatom, og X og R2 er som angitt ovenfor, med et amin svarende til gruppen Z angitt ovenfor, eller b) for fremstilling av en forbindelse med formelenhvor X, R2 og R4 er som angitt ovenfor, 1) omsettes en forbindelse med formelenhvor R1 er C1-C4 alkyl,med en forbindelse med formelenhvor Hal er halogen; 2) halogenatomet i den resulterende forbindelse med formelenutskiftes med en aminogruppe med formelen HR4N- eller med et azid-ion; 3) den resulterende azidgruppe reduseres for å gi en forbindelse hvor R4 er hydrogen, og 4) eventuelt alkyleres aminogruppen med et alkylhalogenid hvor alkylgruppen har 1 til 3 karbonatomer, og 5) forbindelsen med. formel I oppnås ved sur hydrolyse,og eventuelt omdannes det resulterende produkt til et farma-søytisk godtagbart syreaddisjonssalt eller basesalt derav ved kjente metoder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41640682A | 1982-09-09 | 1982-09-09 | |
US52227583A | 1983-08-12 | 1983-08-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO833206L NO833206L (no) | 1984-03-12 |
NO164418B true NO164418B (no) | 1990-06-25 |
NO164418C NO164418C (no) | 1990-10-03 |
Family
ID=27023343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO833206A NO164418C (no) | 1982-09-09 | 1983-09-08 | Analogifremgangsmaate for fremstilling av terapeutisk aktive naftyridin- og kinolin-karboksylsyre-forbindelser. |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0106489B1 (no) |
JP (5) | JPH0742284B2 (no) |
KR (1) | KR890001424B1 (no) |
AU (1) | AU562286B2 (no) |
CA (1) | CA1340721C (no) |
CS (1) | CS246065B2 (no) |
DD (1) | DD216010A5 (no) |
DE (1) | DE3377493D1 (no) |
DK (2) | DK171098B1 (no) |
ES (6) | ES8502687A1 (no) |
FI (1) | FI83513C (no) |
GR (1) | GR79059B (no) |
HU (1) | HU196986B (no) |
IE (1) | IE55898B1 (no) |
IL (1) | IL69601A (no) |
NO (1) | NO164418C (no) |
NZ (1) | NZ205529A (no) |
OA (1) | OA07527A (no) |
PH (1) | PH21530A (no) |
PT (1) | PT77308B (no) |
ZA (1) | ZA836357B (no) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4665079A (en) * | 1984-02-17 | 1987-05-12 | Warner-Lambert Company | Antibacterial agents |
US5281612A (en) * | 1982-09-09 | 1994-01-25 | Warner-Lambert Company | Naphthyridine antibacterial agents |
DE3318145A1 (de) * | 1983-05-18 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | 7-amino-1-cyclopropyl-6,8-difluor-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
CS274601B2 (en) * | 1983-07-27 | 1991-09-15 | Dainippon Pharmaceutical Co | Method of 1,8-naphthyridine derivative production |
JPS60260577A (ja) * | 1984-06-06 | 1985-12-23 | Dainippon Pharmaceut Co Ltd | 1,8−ナフチリジン誘導体 |
AU553415B2 (en) * | 1983-09-19 | 1986-07-17 | Abbott Japan Co., Ltd. | 6-fluoro-1-4-dihydro-4-oxo-7-substituted piperazinyl- quinoline-3-carboxylic acids |
DE3574380D1 (en) * | 1984-02-17 | 1989-12-28 | Daiichi Seiyaku Co | 1,8-naphthyridine derivatives |
US4571396A (en) * | 1984-04-16 | 1986-02-18 | Warner-Lambert Company | Antibacterial agents |
JPS60228479A (ja) * | 1984-04-26 | 1985-11-13 | Toyama Chem Co Ltd | 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩 |
DE3420798A1 (de) * | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | 7-(3-aryl-l-piperazinyl)- sowie 7-(3-cyclohexyl-l-piperazinyl)-3-chinoloncarbonsaeuren |
US4604401A (en) * | 1984-07-20 | 1986-08-05 | Warner-Lambert Company | Antibacterial agents III |
IE58742B1 (en) * | 1984-07-20 | 1993-11-05 | Warner Lambert Co | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de] [1,4]benzoxauine-6-carboxylic acids; sibstituted-5-amino-6-6fluoro-4-oxo.1,4-dihydroquinoline-3 carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1.8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds |
AU576272B2 (en) * | 1984-11-13 | 1988-08-18 | Kyorin Pharmaceutical Co. Ltd. | Quinolone carboxylic acid derivates |
IN162769B (no) * | 1984-11-13 | 1988-07-09 | Kyorin Seiyaku Kk | |
DE3508816A1 (de) * | 1985-01-10 | 1986-07-10 | Bayer Ag, 5090 Leverkusen | 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren |
US4851535A (en) * | 1985-01-23 | 1989-07-25 | Toyama Chemical Co., Ltd. | Nicotinic acid derivatives |
EP0193283A1 (en) * | 1985-02-02 | 1986-09-03 | Beecham Group Plc | Thiazoloquinoline derivatives, process for their preparation and compositions containing them |
JPH0635458B2 (ja) * | 1985-02-15 | 1994-05-11 | 大日本製薬株式会社 | ピリドンカルボン酸誘導体、そのエステルおよびその塩 |
AU578793B2 (en) * | 1985-02-15 | 1988-11-03 | Dainippon Pharmaceutical Co. Ltd. | Novel 1,8-naphthyridine derivatives and processes for preparation thereof |
JPS61243081A (ja) * | 1985-04-19 | 1986-10-29 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸誘導体、そのエステルおよびその塩 |
AU5427286A (en) * | 1985-03-08 | 1986-09-11 | Kyorin Pharmaceutical Co. Ltd. | 7-(1-pyrrolidinyl)-3-quinolinecarboxylic acid derivatives |
DE3509546A1 (de) * | 1985-03-16 | 1986-09-25 | Bayer Ag, 5090 Leverkusen | 7-amino-1-(subst.cyclopropyl)-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
IL77846A (en) * | 1985-03-25 | 1989-08-15 | Warner Lambert Co | Process for the preparation of 7-amino-quinolin-4-oxy-3-carboxylic acid derivatives |
US4578473A (en) * | 1985-04-15 | 1986-03-25 | Warner-Lambert Company | Process for quinoline-3-carboxylic acid antibacterial agents |
US4657913A (en) * | 1985-04-18 | 1987-04-14 | Warner-Lambert Company | Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents |
EP0207420B1 (en) * | 1985-06-26 | 1992-05-06 | Daiichi Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives |
JPH0635457B2 (ja) * | 1985-06-28 | 1994-05-11 | 杏林製薬株式会社 | ピリドンカルボン酸誘導体およびその製造方法 |
IN166416B (no) * | 1985-09-18 | 1990-05-05 | Pfizer | |
JPH0637489B2 (ja) * | 1985-09-21 | 1994-05-18 | 杏林製薬株式会社 | キノロンカルボン酸誘導体およびその製造方法 |
JPS62108878A (ja) * | 1985-11-05 | 1987-05-20 | Kyorin Pharmaceut Co Ltd | キノロンカルボン酸誘導体およびその製造方法 |
US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
JPS62228063A (ja) * | 1985-12-27 | 1987-10-06 | Sankyo Co Ltd | キノリンカルボン酸誘導体 |
US4772706A (en) * | 1986-01-13 | 1988-09-20 | Warner-Lambert Company | Process for quinoline-3-carboxylic acid antibacterial agents |
JP2598737B2 (ja) * | 1986-01-21 | 1997-04-09 | 杏林製薬 株式会社 | 選択毒性に優れた8−アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
JPH089597B2 (ja) * | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
US4692454A (en) * | 1986-02-03 | 1987-09-08 | Warner-Lambert Company | Opthalmic use of quinolone antibiotics |
JPS62205060A (ja) * | 1986-03-04 | 1987-09-09 | Kyorin Pharmaceut Co Ltd | 8位置換キノロンカルボン酸誘導体 |
JPS63198664A (ja) * | 1986-03-31 | 1988-08-17 | Sankyo Co Ltd | キノロンカルボン酸誘導体 |
FI871419A (fi) * | 1986-03-31 | 1987-10-01 | Sankyo Co | Kinolin-3-karboxylsyraderivat, deras framstaellning och anvaendning. |
US4689423A (en) * | 1986-04-01 | 1987-08-25 | Warner-Lambert Company | Process for the preparation of 2,3,4,5-tetrafluorobenzoyl acetates |
US4771055A (en) * | 1986-07-28 | 1988-09-13 | Warner-Lambert Company | 7-[[3-(aminomethyl)-3-alkyl]-1-pyrrolidinyl]-quinoline-carboxylic acids |
JPS6416767A (en) * | 1987-07-09 | 1989-01-20 | Dainippon Pharmaceutical Co | 8-halogenoquinoline derivative, its ester and salt |
US4851418A (en) * | 1987-08-21 | 1989-07-25 | Warner-Lambert Company | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent |
IT1222833B (it) * | 1987-10-06 | 1990-09-12 | Mediolanum Farmaceutici Srl | Derivati pirido benzotiazinici dotati di elevata attivita' antibatterica e di elevata biodisponibilita' tissutale |
HU205105B (en) * | 1987-10-26 | 1992-03-30 | Pfizer | Process for producing azetidinyl quinoline carboxylic acids and pharmaceutical compositions comprising same |
WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
FR2625200A1 (en) * | 1987-12-29 | 1989-06-30 | Esteve Labor Dr | 7-(1-Azetidinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and their application as medicaments |
FR2634483B2 (fr) * | 1987-12-29 | 1994-03-04 | Esteve Labor Dr | Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments |
JP2844079B2 (ja) * | 1988-05-23 | 1999-01-06 | 塩野義製薬株式会社 | ピリドンカルボン酸系抗菌剤 |
KR910003630B1 (ko) * | 1988-06-17 | 1991-06-07 | 한국과학기술원 | 벤조일 아세틱 에스테르 유도체 및 그 제조방법 |
DE3906365A1 (de) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
WO1990002123A1 (en) * | 1988-08-23 | 1990-03-08 | Pfizer Inc. | Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters |
FR2649106A2 (fr) * | 1989-06-29 | 1991-01-04 | Esteve Labor Dr | Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicament |
FR2654728B2 (fr) * | 1989-03-16 | 1994-09-23 | Esteve Labor Dr | Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicament. |
FR2644455B1 (fr) * | 1989-03-16 | 1994-09-23 | Esteve Labor Dr | Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicaments |
NO177302C (no) * | 1989-03-16 | 1995-08-23 | Esteve Labor Dr | Analogifremgangsmåte til fremstilling av terapeutisk aktive substituerte azetidinylkinolon(naftyridon)karboksylsyrederivater |
DE3930262A1 (de) * | 1989-09-11 | 1991-03-21 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3930266A1 (de) * | 1989-09-11 | 1991-03-14 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
KR910009333B1 (ko) * | 1989-10-23 | 1991-11-11 | 재단법인 한국화학연구소 | 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법 |
KR910009331B1 (ko) * | 1989-10-23 | 1991-11-11 | 재단법인 한국화학연구소 | 디아자비시클로아민 화합물과 그의 제조방법 |
KR910009330B1 (ko) * | 1989-10-23 | 1991-11-11 | 재단법인 한국화학연구소 | 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법 |
JP2644610B2 (ja) * | 1990-06-12 | 1997-08-25 | 三共株式会社 | キノロンカルボン酸誘導体 |
DE4032560A1 (de) * | 1990-10-13 | 1992-04-16 | Bayer Ag | 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate |
WO1992009579A1 (en) * | 1990-11-30 | 1992-06-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Quinolonecarboxylic acid compound and its use |
FR2676445B1 (fr) * | 1991-05-16 | 1995-02-03 | Esteve Labor Dr | Derives de pyridone amino acide azetidinyl substitues, leur preparation et leur application en tant que medicaments. |
WO1993013101A1 (en) * | 1991-12-27 | 1993-07-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound |
JPH072783A (ja) * | 1993-11-26 | 1995-01-06 | Sankyo Co Ltd | キノリンカルボン酸誘導体の製造中間体 |
JP2716952B2 (ja) * | 1995-09-08 | 1998-02-18 | 三共株式会社 | 8−メトキシキノロンカルボン酸誘導体の製造中間体 |
JPH08208617A (ja) * | 1995-11-02 | 1996-08-13 | Sankyo Co Ltd | キノリンカルボン酸誘導体の製造中間体 |
TW425394B (en) * | 1996-04-24 | 2001-03-11 | Daiichi Seiyaku Co | Antimicrobial quinolone derivatives having 3-(N-cycloalkyl) aminomethylpyrrolidine group |
DE69732635T2 (de) | 1996-07-12 | 2005-12-29 | Daiichi Pharmaceutical Co., Ltd. | Cis-substituierte aminocyclopropanderivate |
TR200001435T2 (tr) | 1997-09-15 | 2000-08-21 | The Procter & Gamble Company | Antimikrobiyal kuinolonlar, bunların bileşimleri ve kullanımları |
DE19751948A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren |
US7514451B2 (en) * | 2003-09-10 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative |
JP5097967B2 (ja) | 2006-03-28 | 2012-12-12 | タイゲン バイオテクノロジー カンパニー,リミテッド | リンゴ酸塩類、及び(3s,5s)−7−[3−アミノ−5−メチルーピペリジニル]−1−シクロプロピル−1,4−ジヒドロ−8−メトキシ−4−オキソ−3−キノリンカルボン酸の多形体類 |
KR20110082635A (ko) | 2006-03-28 | 2011-07-19 | 워너 칠콧 컴퍼니 엘엘씨 | 퀴놀론 중간체를 제조하기 위한 커플링 방법 |
US8222407B2 (en) | 2007-05-24 | 2012-07-17 | Kyorin Pharmaceutical Co., Ltd. | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position |
CN104817537A (zh) * | 2015-04-24 | 2015-08-05 | 河南大学 | 一种1-环丙基-7-氨甲基三唑-氟喹诺酮羧酸类衍生物及其制备方法和应用 |
CN104803975A (zh) * | 2015-04-24 | 2015-07-29 | 河南大学 | 一种氨甲基三唑取代的二氟喹诺酮羧酸类衍生物及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133082A (en) * | 1960-06-09 | 1964-05-12 | Mead Johnson & Co | 1-substituted-3-pyrrolidylmethylamines |
US3590036A (en) * | 1968-11-18 | 1971-06-29 | George Y Lesher | Naphthyridine-3-carboxylic acids,their derivatives and preparation thereof |
US3753993A (en) * | 1971-05-17 | 1973-08-21 | Sterling Drug Inc | 1,4-dihydro-4-oxo-7-pyridyl-3-quinoline-carboxylic acid derivatives |
AR204162A1 (es) * | 1972-05-08 | 1975-11-28 | Yamanouchi Pharma Co Ltd | Proceso para la preparacion de derivados de ampicilina |
US3876650A (en) * | 1973-03-08 | 1975-04-08 | Sterling Drug Inc | 3-dialkylaminomethyl-1,4-dihydro-4-oxo-1,8-naphthyridines |
JPS5466686A (en) * | 1977-09-20 | 1979-05-29 | Dainippon Pharmaceut Co Ltd | Quinoline-3-carboxylic acid derivative, its preparation, and pharmaceutical composition containig the same |
JPS5649382A (en) * | 1979-09-28 | 1981-05-02 | Dainippon Pharmaceut Co Ltd | 6-fluoro-7-cyclic amino-1,8-naphthylidine derivative and its salt |
JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
JPS5770889A (en) * | 1980-10-21 | 1982-05-01 | Dainippon Pharmaceut Co Ltd | 1-ethyl-1,8-naphthyridine derivative and salt thereof |
JPS5772981A (en) * | 1980-10-22 | 1982-05-07 | Dainippon Pharmaceut Co Ltd | 1,8-naphthyridine derivative and its salt |
JPS57142983A (en) * | 1981-02-27 | 1982-09-03 | Dainippon Pharmaceut Co Ltd | 1-vinyl-1,8-naphthyridine derivative and its salt |
JPS57146775A (en) * | 1981-03-06 | 1982-09-10 | Dainippon Pharmaceut Co Ltd | 1,8-naphthyridine derivative and its salt |
US4382937A (en) * | 1981-02-27 | 1983-05-10 | Dainippon Pharmaceutical Co., Ltd. | Naphthyridine derivatives and their use as anti-bacterials |
DE3420743A1 (de) * | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | 7-amino-1-cyclopropyl-6,8-dihalogen-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
JPS61225181A (ja) * | 1986-02-04 | 1986-10-06 | Kyorin Pharmaceut Co Ltd | キノロンカルボン酸誘導体及びその製造方法 |
JP2816798B2 (ja) * | 1993-08-02 | 1998-10-27 | ワイケイケイアーキテクチュラルプロダクツ株式会社 | 外装パネル |
-
1983
- 1983-08-22 IE IE1961/83A patent/IE55898B1/en not_active IP Right Cessation
- 1983-08-26 ZA ZA836357A patent/ZA836357B/xx unknown
- 1983-08-30 IL IL69601A patent/IL69601A/xx unknown
- 1983-09-05 AU AU18698/83A patent/AU562286B2/en not_active Expired
- 1983-09-05 FI FI833151A patent/FI83513C/fi not_active IP Right Cessation
- 1983-09-06 EP EP83305148A patent/EP0106489B1/en not_active Expired
- 1983-09-06 DE DE8383305148T patent/DE3377493D1/de not_active Expired
- 1983-09-07 GR GR72396A patent/GR79059B/el unknown
- 1983-09-07 CS CS836498A patent/CS246065B2/cs unknown
- 1983-09-08 HU HU833140A patent/HU196986B/hu unknown
- 1983-09-08 OA OA58095A patent/OA07527A/xx unknown
- 1983-09-08 NO NO833206A patent/NO164418C/no not_active IP Right Cessation
- 1983-09-08 JP JP58164271A patent/JPH0742284B2/ja not_active Expired - Lifetime
- 1983-09-08 CA CA000436241A patent/CA1340721C/en not_active Expired - Fee Related
- 1983-09-08 DK DK407483A patent/DK171098B1/da not_active IP Right Cessation
- 1983-09-08 ES ES525493A patent/ES8502687A1/es not_active Expired
- 1983-09-08 NZ NZ205529A patent/NZ205529A/en unknown
- 1983-09-08 PT PT77308A patent/PT77308B/pt unknown
- 1983-09-08 DD DD83254624A patent/DD216010A5/de not_active IP Right Cessation
- 1983-09-08 PH PH29512A patent/PH21530A/en unknown
- 1983-09-09 KR KR1019830004239A patent/KR890001424B1/ko not_active IP Right Cessation
-
1984
- 1984-02-22 ES ES529934A patent/ES8505673A1/es not_active Expired
- 1984-02-22 ES ES529933A patent/ES529933A0/es active Granted
- 1984-02-22 ES ES529935A patent/ES8506309A1/es not_active Expired
- 1984-02-22 ES ES529936A patent/ES8506020A1/es not_active Expired
- 1984-02-22 ES ES529937A patent/ES8506021A1/es not_active Expired
-
1988
- 1988-11-10 JP JP63282640A patent/JPH01146880A/ja active Pending
-
1991
- 1991-02-27 JP JP3053587A patent/JPH0662561B2/ja not_active Expired - Lifetime
-
1994
- 1994-03-02 JP JP6032109A patent/JPH0780770B2/ja not_active Expired - Lifetime
- 1994-06-16 DK DK070094A patent/DK170471B1/da not_active IP Right Cessation
-
1996
- 1996-05-29 JP JP8134697A patent/JP2704984B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO164418B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive naftyridin- og kinolin-karboksylsyre-forbindelser. | |
KR900004995B1 (ko) | 항균성 카복실산류 | |
KR940000368B1 (ko) | 신규 퀴놀린 카르본산 유도체 | |
NO162560B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive naftyridin-, kinolin- og benzoksazin-karboksylsyrer. | |
CA1277661C (en) | Process for quinoline-3-carboxylic acid antibacterial agents | |
NO168889B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(1-pyrrolidinyl)-3-chinolon- og naftyridonkarboksylsyre-derivater, saavel som substituerte (oksa)diazabicyklooktan og -nonan | |
JP2003026574A (ja) | 抗バクテリア剤 | |
US4777175A (en) | Antibacterial agents | |
JPS624284A (ja) | ピリドンカルボン酸誘導体およびその製造方法 | |
NO158060B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonforbindelser. | |
US4772706A (en) | Process for quinoline-3-carboxylic acid antibacterial agents | |
NO862042L (no) | Antibakterielt virksomme chinolonkarboksylsyreestere. | |
US5910498A (en) | Pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents comprising the same as active ingredient | |
AU648212B2 (en) | Azetidine compounds | |
SU1360584A3 (ru) | Способ получени нафтиридинхинолин-или бензоксазинкарбоновых кислот или их фармацевтически допустимых солей присоединени кислоты | |
KR101400568B1 (ko) | 치환된 퀴놀론 ⅲ | |
NO861172L (no) | Fremgangsmaate for fremstilling av kinolinkarboksylsyre-derivater. | |
SU1456015A3 (ru) | Способ получени производных 1,8-нафтиридина или их кислотно-аддитивных солей (его варианты) | |
US20040029915A1 (en) | Optically active quinoline carboxylic acid derivatives with 7-pyrrolidine substituents causing optical activity and a process for the preparation thereof | |
KR101419087B1 (ko) | 퀴놀론카르복실산 유도체의 제법 | |
JP2552101B2 (ja) | 新規ピリドンカルボン酸誘導体及びその調製方法 | |
RU2120941C1 (ru) | Производные хинолонкарбоновых кислот или их фармацевтически приемлемые соли | |
DD283385A5 (de) | Verfahren zur herstellung von derivaten der 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinolein-3-carboxylsaeure | |
CZ97496A3 (en) | Process for preparing 1-cyclopropyl-6-fluoro-1, 4-dihydro-7-£(1s, 4s)|-5-methyl-2,5-diazabicyclo £2.2.1|hept-2-yl|-4-oxo-3-quinolinecarboxylic acid and salts thereof | |
IE19970856A1 (en) | 7-(1-Pyrrolidinyl)-3-quinolone and naphthyridone carboxylic acid derivatives, method for their preparation and for substituted mono- and bicyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |
Free format text: EXPIRED IN SEPTEMBER 2003 |